Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of Autistic Disorder (299.00)~* ABC-I Subscale score of greater than or equal to 18~* CGI-S of greater than or equal to 4~* mental age \>18 months, body weight of at least 20 kg, seizure-free for at least 6 consecutive months and if on anticonvulsants must be on a dosage that has been stable for at least 4 weeks~* Medication free for 1 week before the start of the study for all psychotropic drugs, except 4 weeks for fluoxetine and at least 8 weeks for injectable medications~* Female patients must be premenarchal or sexually abstinent or, if heterosexually active, must practice an effective method of birth control.~Exclusion Criteria:~* History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's~* Any history of hypersensitivity to risperidone, or its excipients in formulation, or other known drug allergy~* Patients who received risperidone within 3 months before screening (except p.r.n. use)~* Patients who did not demonstrate sufficient clinical response to an adequate trial of risperidone treatment in the past (an adequate trial is defined as a period of at least 4 weeks at an adequate dose)~* Neurologic disorder (e.g., Neuroleptic Malignant Syndrome, seizure disorders that are unstable, seizure activity within the past 6 months)~* History of alcohol or substance dependence within 3 months of screening~* Female subject who is pregnant (positive beta-HCG) or breast feeding~* Patients with existing moderate or severe EPS or history of tardive dyskinesia~* Patients who have received an experimental drug or used an experimental medical device within 3 months before the planned start of treatment.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Risperidone low dose Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
- 002 (Type: EXPERIMENTAL): Risperidone high dose Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
- 003 (Type: PLACEBO_COMPARATOR): Placebo Oral solution qd or bid for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).